AMAT vs. APH, SGM, MSI, MCP, BERI, STM, ATOM, INSG, INDI, and MIND
Should you be buying Amati AIM VCT stock or one of its competitors? The main competitors of Amati AIM VCT include Alliance Pharma (APH), Sigma Capital Group (SGM), MS INTERNATIONAL (MSI), Martin Currie Asia Unconstrand Trust (MCP), BlackRock Energy and Resources (BERI), STM Group (STM), Atome (ATOM), Insig AI (INSG), Indus Gas (INDI), and Mind Gym (MIND). These companies are all part of the "electronic equipment" industry.
Amati AIM VCT vs. Its Competitors
Amati AIM VCT (LON:AMAT) and Alliance Pharma (LON:APH) are both small-cap electronic equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.
Amati AIM VCT pays an annual dividend of GBX 5 per share and has a dividend yield of 8.1%. Alliance Pharma pays an annual dividend of GBX 2 per share and has a dividend yield of 3.1%. Amati AIM VCT pays out -68.7% of its earnings in the form of a dividend. Alliance Pharma pays out -32.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amati AIM VCT is clearly the better dividend stock, given its higher yield and lower payout ratio.
Amati AIM VCT has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Alliance Pharma has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.
Alliance Pharma has a consensus price target of GBX 6,250, indicating a potential upside of 9,559.97%. Given Alliance Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Alliance Pharma is more favorable than Amati AIM VCT.
Amati AIM VCT has higher earnings, but lower revenue than Alliance Pharma. Alliance Pharma is trading at a lower price-to-earnings ratio than Amati AIM VCT, indicating that it is currently the more affordable of the two stocks.
66.3% of Alliance Pharma shares are held by institutional investors. 0.5% of Amati AIM VCT shares are held by insiders. Comparatively, 12.0% of Alliance Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Amati AIM VCT had 1 more articles in the media than Alliance Pharma. MarketBeat recorded 1 mentions for Amati AIM VCT and 0 mentions for Alliance Pharma. Alliance Pharma's average media sentiment score of 0.00 beat Amati AIM VCT's score of -0.64 indicating that Alliance Pharma is being referred to more favorably in the news media.
Amati AIM VCT has a net margin of 190.46% compared to Alliance Pharma's net margin of -18.34%. Amati AIM VCT's return on equity of -14.97% beat Alliance Pharma's return on equity.
Summary
Alliance Pharma beats Amati AIM VCT on 10 of the 17 factors compared between the two stocks.
Get Amati AIM VCT News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMAT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AMAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amati AIM VCT Competitors List
Related Companies and Tools
This page (LON:AMAT) was last updated on 7/26/2025 by MarketBeat.com Staff
